Olivier Molinier

Dr. Olivier Molinier


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

27 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GHGuillaume Herbreteau
Guillaume Herbreteau
ALAlexandra Langlais
Alexandra Langlais
LGLaurent Greillier
Laurent Greillier
CAClarisse Audigier-Valette
Clarisse Audigier-Valette
LULionel Uwer
Lionel Uwer
JPJean-Louis Pujol
Jean-Louis Pujol
Background: The IFCT-1603 trial evaluated atezolizumab in small cell lung cancer (SCLC). The purpose of the present study was to determine whether circulating tumor DNA (ctDNA), prospectively collected at treatment initiation, was associated with the prognosis of SCLC, and whether it identified patients who benefited from atezolizumab. Methods: 68 patients were included in this study: 46 patients were treated with atezolizumab and 22 with conventional chemotherapy. Circulating DNA was extracted from plasma and NGS (Next Generation Sequencing) looked for mutations in the TP53, RB1, NOTCH1, NOTCH2, and NOTCH3 genes. ctDNA was detectable when at least one somatic mutation was identified, and its relative abundance was quantified by the variant allele fraction (VAF) of the most represented mutation. Results: We found that 49/68 patients (70.6%) had detectable baseline ctDNA. The most frequently identified mutations were TP53 (32/49; 65.3%) and RB1 (25/49; 51.0%). Patients with detectable ctDNA had a significantly lower disease control rate at week 6 compared with patients with no detectable ctDNA, regardless of the nature of the treatment. Detection of ctDNA was associated with a poor OS prognosis. The detection of ctDNA at a relative abundance greater than the median value was significantly associated with poor overall survival (OS) and progression free survival (PFS). Interestingly, the benefit in overall survival (OS) associated with low ctDNA was more pronounced in patients treated with atezolizumab than in patients receiving chemotherapy. Among patients whose relative ctDNA abundance was below the median, those treated with atezolizumab tended to have higher OS than those in the chemotherapy arm. Conclusion: ctDNA is strongly associated with the prognosis of SCLC patients treated with second-line immunotherapy. Its analysis seems justified for future SCLC clinical trials.

1 March 2020 in Respiratory Medicine and Research
Verified
Journal Article
Closed access
OMOlivier Molinier
Olivier Molinier
FGF. Goupil
F. Goupil
DDD. Debieuvre
D. Debieuvre
JAJ.-B. Auliac
J.-B. Auliac
SJS. Jeandeau
S. Jeandeau
MGM. Grivaux
M. Grivaux

2 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
VGValérie Gounant
Valérie Gounant
MDMichael Duruisseaux
Michael Duruisseaux
Ghassen SoussiGhassen Soussi
Ghassen Soussi
SHSylvie Van Hulst
Sylvie Van Hulst
OBOlivier Bylicki
Olivier Bylicki
GZGérard Zalcman
Gérard Zalcman
Anti-PD-1 antibodies prolong survival of performance status (PS) 0–1 advanced non-small-cell lung cancer (aNSCLC) patients. Their efficacy in PS 3–4 patients is unknown. Conse- cutive PS 3–4 aNSCLC patients receiving compassionate nivolumab were accrued by 12 French thoracic oncology departments, over 24 months. Overall survival (OS) was calculated using the Kaplan-Meier method. Prognostic variables were assessed using Cox proportional hazards models. Overall, 35 PS 3–4 aNSCLC patients (median age 65 years) received a median of 4 nivolumab infusions (interquartile range [IQR], 1–7) as first- (n = 6) or second-line (n = 29) therapy. At a median of 52-month follow-up (95%CI, 41–63), 32 (91%) patients had died. Median progression-free survival was 2.1 months (95%CI, 1.1–3.2). Median OS was 4.4 months (95%CI, 0.5–8.2). Overall, 20% of patients were alive at 1 year, and 14% at 2 years. Treatment-related adverse events occurred in 8/35 patients (23%), mostly of low-grade. After adjustment, brain metastases (HR = 5.2; 95%CI, 9–14.3, p = 0.001) and <20 pack-years (HR = 4.8; 95%CI, 1.7–13.8, p = 0.003) predicted worse survival. PS improvement from 3–4 to 0–1 (n = 9) led to a median 43-month (95%CI, 0–102) OS. Certain patients with very poor general condition could derive long-term benefit from nivolumab salvage therapy.

1 March 2022 in Clinical Lung Cancer
Verified
Journal Article
Closed access
FPFrançois Pinquie
François Pinquie
ACAlexis B. Cortot
Alexis B. Cortot
LCLouise-Marie Chevalier
Louise-Marie Chevalier
AMAlain Morel
Alain Morel
JSJérémy Sandrini
Jérémy Sandrini
OMOlivier Molinier
Olivier Molinier

6 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
OMOlivier Molinier
Olivier Molinier
CGCamille Guguen
Camille Guguen
MMMarie Marcq
Marie Marcq
ACAnne-Laure Chene
Anne-Laure Chene
PMPhilippe Masson
Philippe Masson
TUThierry Urban
Thierry Urban
The consequences of the strict health restrictions during the first wave of COVID-19 on lung cancer (LC) patients are not known. This cohort study evaluated the impact of the initial lockdown on management of and long-term outcome in LC patients. This exposed–unexposed-type study included two evaluation periods of 6 months each in non-selected patients; one began on the first day of lockdown in 2020, and the other in 2019 during the same calendar period. Various indicators were compared: clinical profiles, management delays and overall survival beyond 2 years. A total of 816 patients from 7 public or private centers were enrolled. The clinical characteristics of the patients in 2020 did not differ from those in 2019, except that the population was older (p = 0.002) with more non-smokers (p = 0.006). Delays for pre-therapeutic medical management were generally reduced after the first imaging in 2020 (1.28 [1.1–1.49]). In the multivariate analysis, being part of the 2020 cohort was correlated with better prognosis (HR = 0.71 [0.5–0.84], p < 0.001). The gain observed in 2020 mainly benefited non-smoking patients, along with ECOG PS 0–2 (p = 0.01), stage 4 (p = 0.003), squamous cell carcinoma (p = 0.03) and receiving systemic therapy (p = 0.03). In conclusion, the first lockdown did not exert any deleterious impact on LC patients.